{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:08:55Z","timestamp":1777036135885,"version":"3.51.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma is a significant cause of mortality, and treatments for patients with relapsed\/refractory multiple myeloma have limited efficacy. Treatment regimens with belantamab mafodotin have demonstrated significant improvement in progression-free survival compared with current standard-of-care regimens but have been associated with an increased risk of ocular adverse events (OAEs). These practice guidelines aim to provide recommendations to support Japanese clinicians in managing OAEs and facilitate confidence in the use of belantamab mafodotin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An expert panel of Japanese haematologists\/oncologists and ophthalmologists convened to discuss and agree on the recommendations for managing OAEs in patients treated with belantamab mafodotin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The expert panel identified four key themes and 13 clinical questions to guide the recommendations for managing belantamab mafodotin\u2013related OAEs in the real-world setting in Japan. The four key themes were: (i) identification of OAEs associated with belantamab mafodotin treatment; (ii) management and dose modification of belantamab mafodotin treatment for OAEs; (iii) multidisciplinary collaboration for effective management of ocular events; and (iv) a patient-centred approach to the management of OAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The recommendations in these practice guidelines build on published clinical trial evidence and the practical experience of the expert panel to help Japanese clinicians make informed treatment decisions in the management of multiple myeloma in the real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf148","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:34:45Z","timestamp":1758022485000},"page":"1349-1356","source":"Crossref","is-referenced-by-count":3,"title":["Practical guidance on the clinical management of ocular adverse events associated with belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Recommendations from a Japanese expert panel"],"prefix":"10.1093","volume":"55","author":[{"given":"Kazutaka","family":"Sunami","sequence":"first","affiliation":[{"name":"Department of Hematology, NHO Okayama Medical Center , 1711-1 Tamasu, Kitaku, Okayama 701-1192 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Fujisaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Matsuyama Red-Cross Hospital , 1 Bunkyocho, Matsuyama, Ehime 790-8524 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinari","family":"Funaki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Japanese Red Cross Medical Center , 4 Chome-1-22 Hiroo, Shibuya, Tokyo 150-8935 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Ichii","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Osaka University Graduate School of Medicine , 2 Chome-2 Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine , 1 Chrome-1 Idaidori, Yahaba, Shiwa, Iwate 028-3694 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, NHO Shibukawa Medical Centre , 383 Shiroi, Shibukawa, Gunma 377-0204 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh-ichi","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, NHO Okayama Medical Center , 1711-1 Tamasuku, Kita, Okayama 701-1192 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of Internal Medicine, The Jikei University School of Medicine , 3 Chome-25-8 Nishishinbashi, Minato, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhito","family":"Takakuwa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Wakakusa Daiichi Hospital , 1-6 Wakakusacho, Higashiosaka, Osaka 579-8056 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2025120323364407900_ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025120323364407900_ref2","article-title":"Cancer statistics in Japan \u2013 2024","author":"Foundation for Promotion of Cancer Research"},{"key":"2025120323364407900_ref3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"2025120323364407900_ref4","doi-asserted-by":"publisher","first-page":"e0315932","DOI":"10.1371\/journal.pone.0315932","article-title":"Characteristics and treatment patterns in patients with multiple myeloma in Japan: a retrospective cohort analysis","volume":"20","author":"Iida","year":"2025","journal-title":"PLoS One"},{"key":"2025120323364407900_ref5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-023-00804-y","article-title":"Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025120323364407900_ref6","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"2025120323364407900_ref7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"2025120323364407900_ref8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"2025120323364407900_ref9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody\u2013drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"2025120323364407900_ref10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Investig New Drugs"},{"key":"2025120323364407900_ref11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody\u2013drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Therapy"},{"key":"2025120323364407900_ref12","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1016\/S2152-2650(24)02298-5","article-title":"P-396: Characterization and management of ocular events in patients treated with belantamab mafodotin plus bortezomib and dexamethasone in the DREAMM-7 study","volume":"24","author":"Hungria","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025120323364407900_ref13","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1016\/S2152-2650(24)02315-2","article-title":"P-413: Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study","volume":"24","author":"Quach","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025120323364407900_ref14","article-title":"Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed\/refractory multiple myeloma","author":"GSK"},{"key":"2025120323364407900_ref15","article-title":"Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed\/refractory multiple myeloma","author":"GSK"},{"key":"2025120323364407900_ref16","article-title":"Blenrep for I.V. Infusion","author":"GSK"},{"key":"2025120323364407900_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.05.019","article-title":"Practical guidance on the clinical management of belantamab mafodotin for patients with relapsed\/refractory multiple myeloma: recommendations from the Middle East and North Africa expert panel","author":"Beksa\u00e7","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025120323364407900_ref18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025120323364407900_ref19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"2025120323364407900_ref20","doi-asserted-by":"publisher","first-page":"e033940","DOI":"10.1136\/bmjopen-2019-033940","article-title":"Reliability and validity of the Japanese version of the Ocular Surface Disease Index for dry eye disease","volume":"9","author":"Midorikawa-Inomata","year":"2019","journal-title":"BMJ Open"},{"key":"2025120323364407900_ref21","doi-asserted-by":"publisher","first-page":"7530","DOI":"10.1200\/JCO.2024.42.16_suppl.7530","article-title":"Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire","volume":"42","author":"Terpos","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025120323364407900_ref22","first-page":"3044\u20135","volume-title":"HemaSphere","author":"Hajek","year":"2025"},{"key":"2025120323364407900_ref23","doi-asserted-by":"publisher","first-page":"1274659","DOI":"10.3389\/fonc.2023.1274659","article-title":"Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed\/refractory multiple myeloma in the DREAMM-2 study","volume":"13","author":"Cardellino","year":"2023","journal-title":"Front Oncol"},{"key":"2025120323364407900_ref24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.27219","article-title":"Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1\/2 study","volume":"99","author":"Gavriatopoulou","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/12\/1349\/64521663\/hyaf148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/12\/1349\/64521663\/hyaf148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T04:36:48Z","timestamp":1764823008000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/12\/1349\/8276078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2025,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf148","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,6]]}}}